EMA Grants PRIME Status to GSK’s B7-H3-directed ADC, GSK’227, for Recurrent Extensive-stage SCLC
GSK plc has revealed that the European Medicines Agency (EMA) has awarded Priority Medicines (PRIME) status to GSK5764227 (GSK’227), a B7-H3-aimed antibody-drug conjugate (ADC) undergoing trials for patients with recurrent extensive-stage small-cell lung cancer (ES-SCLC). The PRIME Designation facilitates the […]